Nuvilex Inc. (NASDAQ:PMCB) Short Interest Up 95.4% in September

Nuvilex Inc. (NASDAQ:PMCB) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 433,100 shares, a growth of 95.4% from the September 15th total of 221,600 shares. Approximately 7.1% of the company’s stock are short sold. Based on an average daily volume of 95,600 shares, the days-to-cover ratio is currently 4.5 days. Based on an average daily volume of 95,600 shares, the days-to-cover ratio is currently 4.5 days. Approximately 7.1% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Nuvilex Stock Performance

NASDAQ PMCB opened at $0.96 on Thursday. The stock has a 50-day simple moving average of $0.99 and a two-hundred day simple moving average of $1.04. The firm has a market capitalization of $6.53 million, a P/E ratio of -1.78 and a beta of -0.05. Nuvilex has a fifty-two week low of $0.80 and a fifty-two week high of $2.42.

Nuvilex (NASDAQ:PMCB) last released its quarterly earnings data on Monday, September 15th. The company reported ($0.09) earnings per share for the quarter.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.